A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
CONTEXT: Insulin resistance has been proposed as one of the causes of poor glycemic control in overweight/obese youth with type 1 diabetes (T1D). However, the role of adjunctive metformin, an insulin sensitizer, on glycemic control in these patients is unclear. OBJECTIVE: To compare the effect of metformin vs. placebo on hemoglobin A1c (HbA1c), total daily dose (TDD) of insulin, and other parameters in overweight/obese youth with T1D. HYPOTHESIS: Adjunctive metformin therapy will improve glycemic control in overweight/obese youth with T1D. DESIGN, SETTING, AND PARTICIPANTS: A 9-mo randomized, double-blind, placebo controlled trial of metformin and placebo in 28 subjects (13m/15f) of ages 10-20years (y), with HbA1c >8% (64 mmol/mol), BMI >85%, and T1D > 12 months was conducted at a university outpatient facility. The metformin group consisted of 15 subjects (8 m/ 7f), of age 15.0 ± 2.5 y; while the control group was made up of 13 subjects (5m/ 8f), of age 14.5 ± 3.1y. All participants employed a self-directed treat-to-target insulin regimen based on a titration algorithm of (-2)-0-(+2) units to adjust their long-acting insulin dose every 3rd day from -3 mo through +9 mo to maintain fasting plasma glucose (FPG) between 90-120 mg/dL (5.0-6.7 mmol/L). Pubertal maturation was determined by Tanner stage. RESULTS: Over the course of the 9 months of observation, the between-treatment differences in HbA1c of 0.4% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metformin) was not significant (p = 0.903). There were non-significant reduction in fasting plasma glucose (189.4 mg/dL [133.2 to 245.6] for placebo versus 170.5 mg/dL [114.3 to 226.7] for metformin), (p = 0.927); total daily dose (TDD) of short-acting insulin per kg body weight/day(p = 0.936); and the TDD of long-acting insulin per kg body weight per day (1.15 units/kg/day [0.89 to 1.41] for placebo versus 0.90 units/kg/day [0.64 to 1.16] for metformin) (p = 0.221). There was no difference in the occurrence of hypoglycemia between the groups. CONCLUSIONS: This 9-month RCT of adjunctive metformin therapy in overweight and obese youth with T1D resulted in a 0.4% lower HbA1c value in the metformin group compared to the placebo group. TRIAL REGISTRATION: ClinicalTrial.gov NCT01334125.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exercise for type 2 diabetes mellitus
Thomas, D., Elliott, E. J., & Naughton, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002968.pub2 · Cited by 728
Glycemic control in youth with diabetes: the SEARCH for Diabetes in Youth Study
Petitti, D. B., Klingensmith, G. J., Bell, R. A., Andrews, J. S., Dabelea, D., Imperatore, G., Marcovina, S., Pihoker, C., Standiford, D., Waitzfelder, B., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.05.025 · Cited by 397 · cited 1×
“Several socio-demographic and therapeutic factors such as race/ethnicity, socioeconomic status, parental education, parental involvement in diabetes management, family dynamics, and whether a patient receives care from an endocrinologist[23] have been associated with poor glycemic control in youth [23–25].”
BackgroundEffect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
Racial-ethnic disparities in management and outcomes among children with type 1 diabetes
Willi, S. M., Miller, K. M., DiMeglio, L. A., Klingensmith, G. J., Simmons, J. H., Tamborlane, W. V., Nadeau, K. J., Kittelsrud, J. M., Huckfeldt, P., Beck, R. W., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-1774 · Cited by 367 · cited 2×
“The elevated mean HbA1c values in our study are similar to the findings from a recent national report on glycemic control in children and adolescents with T1D which showed higher mean HbA1c level [8.4 ± 1.4% for whites, 9.6 ± 1.9% for blacks, and 8.7 ± 1.6% for Hispanics] than the recently recommended HbA1c target of…”
InfluentialThe use of metformin in type 1 diabetes: a systematic review of efficacy
Vella, S., Buetow, L., Royle, P., Livingstone, S., Colhoun, H. M., & Petrie, J. R. (2010) · Diabetologia · doi:10.1007/s00125-009-1636-9 · Cited by 201 · cited 1×
“A recent meta-analysis of 197 studies on the use of adjunctive metformin therapy in children and adults with T1D concluded that metformin therapy reduces insulin dose requirements in T1D but not HbA1c value[16].”
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents
Abdelghaffar, S., & Attia, A. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006691.pub2 · Cited by 58
Cited by
Obesity and diabetes—Not only a simple link between two epidemics
Chobot, A., Górowska‐Kowolik, K., Sokołowska, M., & Jarosz‐Chobot, P. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3042 · Cited by 281
Libman, I. M., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Katz, M. L., Shah, A., Simmons, J. H., Haller, M. J., Raman, S., Tamborlane, W. V., et al. (2015) · JAMA · doi:10.1001/jama.2015.16174 · Cited by 181
“≥1 Adverse event other than gastrointestinal events 7 (10) [3-17] 15 (22) [12-32] .”
BackgroundMeng, H., Zhang, A., Liang, Y., Hao, J., Zhang, X., & Lu, J. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2983 · Cited by 56
Liu, Y., Chen, C., Chen, Z., Peng, Y., Lin, X., & Xu, L. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3334 · Cited by 36
Metadata
- Authors
- Nwosu, B. U., Maranda, L., Cullen, K., Greenman, L., Fleshman, J., McShea, N., Barton, B. A., & Lee, M. M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-09-14
- Volume
- 10
- Issue
- 9
- Pages
- e0137525
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1666877893
- Cited by
- 49
- References
- 8
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.